Axogen, Inc. (NASDAQ: AXGN)

Axogen, Inc., a leading company in the field of peripheral nerve regeneration and repair, operates under the stock symbol AXGN. The company is dedicated to providing patients with nerve injuries the opportunity to restore nerve function and improve their quality of life. Axogen's products are used in surgical interventions to repair a wide range of physical nerve damage throughout the body, such as lacerations of fingers and complex brachial plexus injuries. The company's platform for peripheral nerve repair includes a comprehensive portfolio of products designed to promote nerve regeneration and repair, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Axotouch Two-Point Discriminator.

Axogen's primary revenue sources come from the distribution of its nerve repair products in the United States and 19 other countries. The company's products are used in various surgical procedures, including trauma, oral maxillofacial, breast reconstruction, and upper extremity compression. Axogen's products are designed to promote nerve regeneration and repair, and are used to treat conditions such as peripheral nerve injuries, compression, and neuroma.

The company's product portfolio includes Avance Nerve Graft, a biologically active nerve implant with more than 15 years of comprehensive clinical evidence and more than 100,000 implants since launch. Axoguard Nerve Connector is a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair. Axoguard Nerve Protector protects and wraps damaged peripheral nerves and reinforces reconstructed nerve gaps while minimizing soft tissue attachments. Axoguard HA+ Nerve Protector provides non-constricting protection for peripheral nerves. Axoguard Nerve Cap protects a peripheral nerve end and separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. Axotouch Two-Point Discriminator measures the innervation density of any surface area of the skin.

Axogen's products have several advantages, including biologically active nerve therapy with more than 10 years of comprehensive clinical evidence, decellularized and cleansed ECM, implantable without the need for immunosuppression, remodels into patient's own tissue, structurally supports the body's own regeneration process, handles similar to an autograft, alleviates tension at the repair site, and a three-year shelf life.

In the peripheral nerve repair market, Axogen is a leading player with a comprehensive portfolio of products used by surgeons around the world. The company's key competitors include Integra LifeSciences, Synthes, and Stryker. However, Axogen's products are differentiated by their biologically active nerve therapy, decellularized and cleansed ECM, and implantable without the need for immunosuppression.